Modus Therapeutics AB

Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.

Sickle Cell Disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow by reducing their pain and the amount of time they will need to spend in hospital. Modus Therapeutics plans to develop a formulation of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.

Kategorier: Pharma

Gå till Modus Therapeutics ABs hemsida